Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, Volume 18, Issue sup1 (2017)

Browse this journal
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, Volume 18, Issue sup1 (2017)

See all volumes and issues
Vol 25, 2024 Vol 24, 2023 Vol 23, 2022 Vol 22, 2021 Vol 21, 2020 Vol 20, 2019 Vol 19, 2018 Volume 18, 2017 Vol 17, 2016 Vol 16, 2015 Vol 15, 2014 Vol 14, 2013 Vol 13, 2012 Vol 12, 2011 Vol 11, 2010 Vol 10, 2009 Vol 9, 2008 Vol 8, 2007 Vol 7, 2006 Vol 6, 2005 Vol 5, 2004 Vol 4, 2003 Vol 3, 2002 Vol 2, 2001 Vol 1, 2000
Download citations Download PDFs Download issue

Edaravone (MCI-186) in Amyotrophic Lateral Sclerosis (ALS). Guest Editor: Angela Genge

Miscellaneous

Article
Full Issue PDF, Volume 18, Issue S1
Pages: 1-103
Published online: 05 Sep 2017
First Page PreviewforFull Issue PDF, Volume 18, Issue S1 | PDF (20.3 MB)
  • 1299 Views
  • 2 CrossRef citations
  • 0Altmetric
Free Access

Research Article

Article
Introduction to supplement: the current status of treatment for ALS
Robert G. Miller & Stanley H. Appel
Pages: 1-4
Published online: 05 Sep 2017
AbstractforIntroduction to supplement: the current status of treatment for ALS | Full Text | References | PDF (131.5 KB)
  • 4567 Views
  • 18 CrossRef citations
  • 0Altmetric
Open Access

Review Article

Review Article
Edaravone and its clinical development for amyotrophic lateral sclerosis
Koji Takei, Kazutoshi Watanabe, Satoshi Yuki, Makoto Akimoto, Takeshi Sakata & Joseph Palumbo
Pages: 5-10
Published online: 05 Sep 2017
AbstractforEdaravone and its clinical development for amyotrophic lateral sclerosis | Full Text | References | PDF (326.3 KB)
  • 9628 Views
  • 53 CrossRef citations
  • 0Altmetric
Open Access

Research Article

Article
A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis
THE EDARAVONE (MCI-186) ALS 16 STUDY GROUP
Pages: 11-19
Published online: 05 Sep 2017
AbstractforA post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis | Full Text | References | PDF (706.4 KB)
  • 4040 Views
  • 41 CrossRef citations
  • 0Altmetric
Open Access

Clinical Trial

Article
Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis
THE WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 17 STUDY GROUP
Pages: 20-31
Published online: 05 Sep 2017
AbstractforExploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis | Full Text | References | PDF (428 KB)
  • 4011 Views
  • 27 CrossRef citations
  • 0Altmetric
Open Access

Research Article

Article
Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis
Fumihiro Takahashi, Koji Takei, Kikumi Tsuda & Joseph Palumbo
Pages: 32-39
Published online: 05 Sep 2017
AbstractforPost-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis | Full Text | References | PDF (582.2 KB)
  • 2691 Views
  • 22 CrossRef citations
  • 0Altmetric
Open Access

Clinical Trial

Article
Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation)
THE WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP
Pages: 40-48
Published online: 05 Sep 2017
AbstractforExploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation) | Full Text | References | PDF (439.5 KB)
  • 4882 Views
  • 36 CrossRef citations
  • 0Altmetric
Open Access

Research Article

Article
Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis
Koji Takei, Fumihiro Takahashi, Shawn Liu, Kikumi Tsuda & Joseph Palumbo
Pages: 49-54
Published online: 05 Sep 2017
AbstractforPost-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis | Full Text | References | PDF (499.2 KB)
  • 3903 Views
  • 21 CrossRef citations
  • 0Altmetric
Open Access

Clinical Trial

Article
Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis
THE WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 19 STUDY GROUP
Pages: 55-63
Published online: 05 Sep 2017
AbstractforOpen-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis | Full Text | References | PDF (973.9 KB)
  • 5973 Views
  • 42 CrossRef citations
  • 0Altmetric
Open Access

Original Article

Article
Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis
Koji Takei, Kikumi Tsuda, Fumihiro Takahashi & Joseph Palumbo
Pages: 64-70
Published online: 05 Sep 2017
AbstractforPost-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis | Full Text | References | PDF (718.9 KB)
  • 2623 Views
  • 14 CrossRef citations
  • 0Altmetric
Open Access

Research Article

Article
A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies
Alexander Kalin, Elvia Medina-Paraiso, Kaoru Ishizaki, Alex Kim, Yannong Zhang, Takanori Saita & Masahiko Wasaki
Pages: 71-79
Published online: 05 Sep 2017
AbstractforA safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies | Full Text | References | PDF (147.2 KB)
  • 2906 Views
  • 14 CrossRef citations
  • 0Altmetric
Open Access
Article
Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations
Yoshinobu Nakamaru, Shuji Kinoshita, Atsuhiro Kawaguchi, Koji Takei, Joseph Palumbo & Masayuki Suzuki
Pages: 80-87
Published online: 05 Sep 2017
AbstractforPharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations | Full Text | References | PDF (881.6 KB)
  • 2949 Views
  • 19 CrossRef citations
  • 0Altmetric
Open Access

Review Article

Review Article
An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe
Koji Takei, Kikumi Tsuda, Fumihiro Takahashi, Manabu Hirai & Joseph Palumbo
Pages: 88-97
Published online: 05 Sep 2017
AbstractforAn assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe | Full Text | References | PDF (176.4 KB)
  • 6642 Views
  • 26 CrossRef citations
  • 0Altmetric
Open Access
Review Article
What can we learn from the edaravone development program for ALS?
Nicholas J. Maragakis
Pages: 98-103
Published online: 05 Sep 2017
AbstractforWhat can we learn from the edaravone development program for ALS? | Full Text | References | PDF (144.1 KB)
  • 3896 Views
  • 14 CrossRef citations
  • 0Altmetric
Open Access

Explore articles